Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 6, 2007, Pages 1905-1911

  Hachem, Ray Y ^a   Chemaly, Roy F ^a   Ahmar, Corine A ^b   Jiang, Ying ^a   Boktour, Maha R ^a   Rjaili, Georges Abou ^b   Bodey, Gerald P ^a   Raad, Issam I ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; COLISTIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN;

ADOLESCENT; ADULT; AGED; APACHE; ARTICLE; BACTEREMIA; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; INFORMATION PROCESSING; INTENSIVE CARE UNIT; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIDRUG RESISTANCE; MULTIPLE REGRESSION; MYELOMA; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEOPLASMS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 34250159829     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01015-06     Document Type: Article

References (36)

1. Aloush, V., S. Navon-Venezia, Y. Seigman-Igra, S. Cabili, and Y. Carmeli. 2006. Multidrug-resistant Pseudomonas aerginosa: risk factors and clinical impact. Antimicrob. Agents Chemother. 50:43-48.
2. Basastaoglu, A. C., H. Gun, M. A. Saracli, M. Bayasallar, and T. Haznedaroglu. 1995. Development of resistance to imipenem among nosocomial isolates of Pseudomonas aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis. 14:469-470.
3. Bennett, J. V. 1974. Session 1. Hospital-acquired infections and the altered host. Nosocomial infections due to Pseudomonas. J. Infect. Dis. 130(Suppl.): S4-S7.
4. Bodey, G. P., R. Bolivar, V. Fainstein, and L. Jadeja. 1983. Infections caused by Pseudomonas aeruginosa. Rev. Infect. Dis. 5:279-313.
5. Burwen, D. R., S. N. Banerjee, R. P. Gaynes, et al. 1994. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J. Infect. Dis. 170:1622-1625.
6. Carmeli, Y., N. Triollet, A. Karchmer, and M. H. Samore. 1999. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch. Intern. Med. 159:1127-1132.
7. Curtin, J. R., G. Petersdorf, and I. L. Bennett, Jr. 1961. Pseudomonas bacteremia: review of ninety-one cases. Ann. Intern. Med. 54:1077-1107.
8. D'Agata, E. M. C. 2004. Rapidly rising prevalence of nosocomial multidrug-resistant, gram-negative bacilli: a 9-year surveillance study. Infect. Control Hosp. Epidemiol. 25:842-846.
9. Douglas, M. W., K. Mulholland, V. Denver, and T. Gottlieb. 2001. Multidrug-resistant Pseudomonas aeruginosa outbreak in a burns unit - an infection control study. Burns 7:131-135.
10. Dubois, V., C. Arpin, B. Melon, et al. 2001. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of β-lactam resistance. J. Clin. Microbiol. 39:2072-2078.
11. Elting, L. S., E. B. Rubenstein, D. V. Rolston, and G. P. Bodey. 1997. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin. Infect. Dis. 2:247-259.
12. Falagas, M. E., K. N. Fragoulis, S. K. Kasiakou, G. J. Sermaidis, and A. Michalopoulos. 2005. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int. J. Antimicrob. Agents 26:504-507.
13. Falagas, M. E., and S. K. Kasiakou. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341.
14. Fish, D. N., J. R. MacLaren, and R. Obritsch. 2003. Surveillance for multidrug-resistance among clinical isolates of Pseudomonas aeruginosa from intensive care units (ICU) in the United States, 1993-2002. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr. C2-1970. American Society for Microbiology, Washington, DC.
15. Garnacho-Montero, J., C. Ortiz-Leyba, F. J. Jimenez-Jimenez, A. R. Barrero-Almodovar, J. L. Garcia-Garmendia, and I. M. Bernabeu-Wittel. 2003. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 36:1111-1118.
16. Garner, J. S., W. R. Jarvis, T. G. Emori, T. C. Horan, and J. M. Hughes. 1996. CDC definition for nosocomial infections. In R. N. Olmstead (ed.), Infection control and applied epidemiology: principles and practice. Mosby, St. Louis, MO.
17. Goodwin, N. J., and E. A. Friedman. 1968. The effects of renal impairment, peritoneal dialysis and hemodialysis on serum sodium colistimethate levels. Ann. Intern. Med. 68:984-994.
18. Hamer, D. H. 2000. Treatment of nosocomial pneumonia and tracheobronchitis caused by multi drug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am. J. Respir. Crit. Care Med. 162:328-330.
19. Levin, A. S., A. A. Barone, J. Penco, et al. 1999. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 28:1008-1011.
20. Linden, P., S. Kusne, K. Coley, P. Fontes, D. J. Kramer, and D. Paterson. 2003. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin. Infect. Dis. 37:e154-e160.
21. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.
22. Markou, N., H. Apostolakos, C. Koumoudiou, et al. 2003. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit. Care 7:R78-R83.
23. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, PA.
24. National Nosocomial Infections Surveillance System. 2002. National Nosocomial Infections Surveillance System report, data summary from January 1992 to June 2002, issued August 2002. Am. J. Infect. Control 30:458-475.
25. Obritsch, M. D., D. N. Fish, R. MacLaren, and R. Jung. 2005. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25:1353-1364.
26. Ostronoff, M., F. Ostronoff, A. Sucupira, et al. 2006. Multidrug-resistant Pseudomonas aeruginosa infection in neutropenic patients successfully treated with a combination of polymyxin B and rifampin. Int. J. Infect. Dis. 10:339-340.
27. Pruitt, B. A., Jr., and R. B. Lindberg. 1979. Pseudomonas aeruginosa infections in burn patients. In R. G. Doggett (ed.), Pseudomonas aeruginosa. Clinical manifestations of infection and current therapy. Academic Press, Inc., New York, NY.
28. Reina, R., E. Estenssoro, G. Sáenz, et al. 2005. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med. 31:1058-1065.
29. Rossello, J., M. Olona, M. Campins, et al. 1992. Investigation of an outbreak of nosocomial infection due to a multiply drug-resistant strain of Pseudomonas aeruginosa. J. Hosp. Infect. 20:87-96.
30. Sobieszczyk, M. E., E. Y. Furuya, C. M. Hay, et al. 2004. Combination therapy with polymyxin B for the treatment of multidrug-resistant gramnegative respiratory tract infections. J. Antimicrob. Chemother. 54:566-569.
31. Talbot, G. H., J. Bradley, J. E. Edwards, Jr., D. Gilbert, M. Scheld, and J. G. Barlett. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668.
32. Tascini, C., G. Gemingnani, S. Ferranti, et al. 2004. Microbiological activity and clinical efficacy of colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infection. J. Chemother. 16:282-287.
33. Troillet, N., M. H. Samore, and Y. Carmeli. 1997. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin. Infect. Dis. 25:1094-1098.
34. Waitz, J. A., and M. J. Weinstein. 1969. Recent microbiological studies with gentamicin. J. Infect. Dis. 119:355-360.
35. Whitecar, J. P., M. Luna, and G. P. Bodey. 1970. Pseudomonas bacteremia in patients with malignant diseases. Am. J. Med. Sci. 260:216-223.
36. Wolinsky, E., and J. D. Hines. 1972. Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. N. Engl. J. Med. 266:759-762.